This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Unlike drugs that alter metabolism or appetite by interacting with hormones, the pill functions entirely mechanically. Traditional methods like diet and exercise often fail to provide long-term success, and newer pharmacological options like hormone-based GLP-1 agonists, while effective, can be expensive and carry side effects.
If the past year is anything to go by, then 2022 will also be a year marked by continued innovations in the lifesciences. Here is a look at some lifescience trends to expect in the coming year, including key themes and topics in the pharmaceutical, biotechnology and medical device industries to keep an eye out for in 2022.
per share, the offering included 1,300,000 ordinary shares, which began trading on the Nasdaq Global Market under the ticker symbol GELS on October 29, 2024. With an expanding patent portfolio and partnerships in human and animal health, Gelteq promotes therapeutic efficacy and patient adherence across diverse health markets.
Eneboparatide (AZP-3601), an investigational parathyroid hormone 1 receptor (PTH1R) agonist, met its primary endpoint in the CALYPSO Phase III trial, offering new data for adults with chronic hypoparathyroidism. AstraZeneca received eneboparatide during its $1.05 Without proper PTH function, patients may face kidney and bone complications.
Doti has worked in industry for the last 14 years, including seven years at AstraZeneca in various roles, and in small markets like Argentina as well as larger global markets. Since 2022, Dr. Doti has been focusing on the US market in hematology and oncology, working in breast, lung, GI and gynecological cancers among others.
Additionally, over a 176-week period, weekly injections of tirzepatide (marketed as Zepbound and Mounjaro) using pooled doses of 5 mg, 10 mg and 15 mg, significantly reduced the risk of disease progression to type 2 diabetes by 94 percent compared with placebo in adult prediabetes patients who were obese or overweight.
a clinical-stage biotech company focused on developing next-gen injectable and oral nutrient-stimulated hormone (NuSH) analog peptides for the treatment of obesity, overweight and related conditions, has priced its initial public offering (IPO) at $18.00 Metsera, Inc., per share, raising $275 million in gross proceeds. billion in 2024 to $37.94
Related: Eli Lillys Zepbound Approved as First Treatment for Obstructive Sleep Apnea The commercial describes Zepbounds mechanism of action as a dual receptor against that works by activating two naturally occurring hormone receptors in [the] body [GLP-1 and GIP-1]. And when it comes to weight loss, change is good, it ends off saying.
Incytes recent announcement on the topline results from two Phase III clinical trials of povorcitinib in patients with hidradenitis suppurativa has stirred both hope and caution in the market. Though as we anticipated, we believe it will likely be relegated to later-line, post-biologics setting given lesser efficacy and safety baggage.
The thyroid plays a critical role in the body by producing hormones that regulate metabolism, heart rate and body temperature among others. Types of Thyroid Conditions There are several different thyroid conditions, with each affecting thyroid hormone production or the gland’s structure, leading to a range of health issues.
Novartis has spent three decades advancing breast cancer treatments, focusing on hormone receptor-positive (HR+), HER2-negative breast cancer, the most common subtype. Last year, the FDA approved Kisqali (ribociclib) to reduce the risk of recurrence in HR+/HER2- early breast cancer.
Glucagon-like peptide-1 (GLP-1) receptor agonists are a newer class of diabetes drugs that have the potential to double as weight loss drugs, widening their lucrative market potentials. Novo’s obesity version of semaglutide (at a higher dose) is marketed as Wegovy and was approved in 2021. billion in 2021 to $61.6 billion by 2030.
It is a complication of Graves disease, an immune system condition that causes the thyroid gland to make excess amounts of thyroid hormone. Slings upcoming Phase III trial will provide further insights into the safety and efficacy of the molecule, as it gears up to compete with Amgen in the thyroid eye disease market.
While the exact physiology of vasomotor symptoms is not fully understood, it is believed that the significant fluctuations in reproductive hormones play a role in triggering these symptoms. Hormone replacement therapy is thought to be one of the most effective treatments for vasomotor symptoms.
Industry professionals will explore the market, innovative formulations and nutritional solutions tailored to empower women toward optimal health and well-being. Research at SRI International has highlighted the relationship between hormonal changes and sleep disruptions and developed systems to manage hot flashes.
The GLP-1 drug market is on its way to becoming one of the most lucrative pharmaceutical markets. Morgan has estimated that the GLP-1 market will surpass $100 billion by 2030, with growth driven equally by use for diabetes and obesity. If you want your company to be featured on Xtalks.com, please email ayeshar@xtalks.com.
For the international market, Novartis will continue to partner with external isotope suppliers. Lutathera is used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that are positive for the hormone receptor somatostatin, including GEP-NETs in the foregut, midgut and hindgut.
The portfolio contains approximately forty-five commercial products, four products in the pipeline, and forty approved non-marketed products, many of which are generics focused on women’s health. Some of the higher-value approved products include contraceptives, such as hormonal vaginal rings and birth control pills.
Pediatric growth hormone deficiency (PGHD) is one such condition, affecting a child’s growth and development. This rare endocrine disorder, characterized by inadequate secretion of growth hormone from the pituitary gland, has profound impacts on physical and sometimes cognitive development.
And now the tirzepatide results could help Lilly continue its market march if it wins approval for it. GLP-1 receptor agonists mimic the action of GLP-1, an intestinal hormone that stimulates the secretion of insulin when blood glucose levels rise. Semaglutide acts by inhibiting glucagon, which is a hormone that increases blood sugar.
The mega biotech acquisition deals, ranging between a quarter to over half a billion dollars, reflects the expanding oncology market, which was valued at $136.7 Despite setbacks due to the pandemic, the market is expected to recover and continue its march forward. The liquid biopsy market itself was valued at over $1.06
It has been a year dominated by the pandemic and many lifesciences research projects were put on hold as big pharma turned its attention to vaccines and therapies. Biogen and Denali will co-market the lead LRRK2 product in the US and China, and Biogen will commercialise in all other markets.
Darbepoetin alfa is a synthetic version of the hormone erythropoietin, which is made in the kidneys and stimulates the production of red blood cells (RBC), or erythrocytes. Kidney dysfunction in CKD leads to impaired production of the hormone, particularly in more advanced disease. Market Size and Regulatory Pathway.
Mounjaro was approved this summer as a Type 2 diabetes treatment and is the first diabetes drug with dual action, targeting two hormones involved in insulin production and appetite (GIP and GLP-1). In its first quarter on the market since its approval, sales totalled $97 million between July and September in the US.
The shares began trading on the Nasdaq Global Market (Nasdaq: SEPN) on October 25, 2024, with a successful closing completed on October 30, 2024. SEP-786, an oral parathyroid hormone 1 receptor (PTH1R) agonist, aims to restore essential mineral balance. Gross proceeds from the offering reached $331.2 million patients in the US.
Incidents such as the hormone replacement therapy drug shortage in early 2022 have shown the damaging impact supply chain issues can have on people who depend on these drugs. This means batch sizes can be tailored to daily demands rather than market forecasts. About the author.
The tablet consists of two hormones: norethindrone acetate, a type of progestin, and ethinyl estradiol, a synthetic form of estrogen. Together, these hormones work to prevent ovulation, alter the uterine lining and thicken cervical mucus, making it more difficult for sperm to reach the egg and for a fertilized egg to implant in the uterus.
Oliver Stohlmann’s Corporate Survival Hacks series draws on his experiences of working in local, regional and global lifescience communications to offer some little tips for enjoying a big business career. This post looks at dealing with sudden stress and turning it into positive energy. Visualise success. About the author.
Exact Sciences is pioneering diagnostics that enable personalised medicine for cancer patients. Additionally, the Oncotype DX® test has been recognised in international healthcare guidelines , and it is these successes in global markets that have paved the way for universal growth. But there is more to be done.
Tirzepatide is a novel investigational obesity treatment that contains mimetics of two hormones that are involved in regulating appetite in a single peptide: a GIP (glucose-dependent insulinotropic polypeptide) receptor agonist and a GLP-1 (glucagon-like peptide-1) receptor agonist. percent and 22.5 percent, respectively, compared to placebo.
Stemline Therapeutics, a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics and a wholly owned subsidiary of the Menarini Group, will market Orserdu in the US. ER+, HER2- Breast Cancer ER+, HER2- cancers account for about 75 percent of breast cancers.
In the dynamic landscape of oncology therapeutics, understanding the trends and performances of leading drugs is crucial for stakeholders across the healthcare and lifesciences sectors. billion, reflecting a 19 percent increase, primarily attributed to expanding market presence in China.
Biologics have emerged as a direct consequence of the rapid development that has taken place in the field of lifesciences, particularly in cell and molecular biology, over the past few decades. Subcutaneous biologics – current market landscape. Our Social Media Platform. Web: [link]. LinkedIn: [link].
Unlike the reigning blockbuster GLP-1 drugs on the market namely Novo Nordisks Wegovy (semaglutide) and Eli Lillys Zepbound (tirzepatide), the latter of which is a dual agonist of the GLP-1 and GIP receptors Amgens MariTide is an antibody-peptide conjugate that combines a GLP-1 receptor agonist (consisting of two peptides that mimic the GLP-1 hormone) (..)
Hypoparathyroidism arises when the parathyroid glands fail to produce enough parathyroid hormone (PTH) or when the PTH produced is ineffective. Ascendis Pharma’s shares climbed to 11 percent in pre-market trading post news of Yorvipath’s approval. Seventy-nine percent of patients (vs.
Symptoms and Etiology: Caused by an overproduction of growth hormone, acromegaly primarily affects adults. By reducing the amount of growth hormone in the blood, progressive enlargement of bones should be slowed. By reducing the amount of growth hormone in the blood, progressive enlargement of bones should be slowed.
Join us as we present an in-depth analysis of each company’s revenue, net income, R&D investments, core therapeutic areas, market presence and strategic collaborations. is a global pharmaceutical company, working across both developed and emerging markets. 2022 Revenue: Pfizer reported an annual revenue of $100.33 Pfizer Inc.
Unlike the reigning blockbuster GLP-1 drugs on the market — namely Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Zepbound (tirzepatide), the latter of which is a dual agonist of the GLP-1 and GIP receptors — Amgen’s MariTide is an antibody-peptide conjugate that combines a GLP-1 receptor agonist (consisting of two peptides that mimic the GLP-1 (..)
Zilebesiran targets angiotensinogen (AGT), part of a hormone system that regulates blood pressure and fluid balance in the body, and according to Alnylam, could treat hypertension effectively when dosed either two or four times a year. .
Norepinephrine is a hormone and neurotransmitter that helps in alertness and maintaining control in high-stress situations. from the previous year owing to the market entry of Strattera generics in the third quarter of 2017. It is predicted that the ADHD market is set to reach $16.9 In 2017, Strattera’s total revenue was $618.2
Speaking at the virtual Capital Markets Day on Wednesday, CEO Werner Baumann emphasized Bayer’s long-term growth perspectives: “Bayer is a leading lifescience company, uniquely positioned at the intersection of health and nutrition – with attractive prospects for growth, earnings and cash flow.”
Recently, Eli Lilly revealed promising results from a mid-stage trial, indicating that its popular drug, tirzepatide (marketed as Zepbound and Mounjaro for weight loss and diabetes, respectively), may be an effective treatment for the fatty liver disease metabolic dysfunction-associated steatohepatitis (MASH).
Rybelsus is Novo’s third semaglutide product on the market, a tablet form of the drug used for the treatment of type 2 diabetes. They mimic the action of GLP-1, a hormone that helps regulate blood sugar levels by enhancing insulin secretion.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content